4.4 Article

Electrochemical Monitoring of Cisplatin as Anticancer Compound to the Treatment of Laryngeal Cancer in the Elederly Using Poly(cyanocobalamin) Modified Composite of Ag Nanoparticles Graphene Oxide Electrode

Journal

Publisher

ELSEVIER
DOI: 10.20964/2022.01.15

Keywords

Cisplatin; Differential pulse voltammetry; Cyanocobalamin; Ag nanoparticles; Graphene oxide; Electropolymerization; Electrodeposition

Funding

  1. Zhaoqing city of Guangdong province Science and Technology Innovation Strategy Special Fund [2018N005]

Ask authors/readers for more resources

The purpose of this research was to develop a new composite material for electrochemical monitoring of cisplatin. The experimental results showed that the composite material had a high porous structure, discrete electroactive sites, and improved electron transfer and signal. Experimental testing demonstrated that the proposed cisplatin sensor had high accuracy for analysis of real samples.
The purpose of this research was to develop a poly(cyanocobalamin) modified composite of Ag nanoparticles graphene oxide (poly(cyc)/Ag-GO) for electrochemical monitoring of cisplatin, a chemotherapy medication used to treat laryngeal cancer. The Ag-GO composite was electrodeposied on a glassy carbon electrode (GCE), and then poly(cyc) was electropolymerized on Ag-GO/GCE. The XRD and FE-SEM structural characterization of Ag-GO nanocomposite revealed that the Ag nanoparticles were discretely distributed on the surface of the GO nanosheets, resulting in a high porous structure with discrete electroactive sites for cyanocobalamin's strong bond and improved electron transfer and signal in electrochemical reactions. Using CV and DPV, electrochemical analyses revealed a stable, sensitive, and selective response of poly(cyc)/Ag-GO/GCE to cisplatin determination. The proposed sensor's detection limit, sensitivity, and linear range were determined to be 0.2 mu M, 0.01316 mu A/mu M, and 40-1200 mu M, respectively. The sensor's capability was tested using prepared platinol injection and human serum as real samples, and the results revealed acceptable recovery (95.25% to 98.50%) and RSD (3.08% to 4.76%), implying that the proposed cisplatin sensor is accurate enough for clinical sample analysis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available